Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Next-Generation Therapeutics for Infectious Diseases Conquer the Global Spotlight

Published: Thursday, March 27, 2014
Last Updated: Thursday, March 27, 2014
Bookmark and Share
Resistance to current drugs spurs treatment innovation in influenza, respiratory syncytial virus, chlamydia and gonorrhea.

The available antivirals for commonly occurring infections such as respiratory syncytial virus (RSV) and influenza are characterized by variable response, poor tolerability and suboptimal dosing regimens, limiting their regular use and efficacy.

Likewise, the development of resistance to almost every recommended antibiotic for bacterial infections like chlamydia and gonorrhoea makes treatment complicated.

Successful commercialization of next-generation therapeutics and the imminent arrival of novel innovative vaccine technologies are expected to address these issues and generate strong growth in the infectious diseases therapeutics market.

New analysis from Frost & Sullivan’s Global Infectious Diseases Therapeutics Market-Influenza, RSV, Chlamydia, and Gonorrhoea finds the influenza vaccine industry is witnessing a shift from conventional egg-based vaccines, which use live attenuated and inactivated viruses, to novel DNA-based, recombinant, sub-unit, and even microbial vector-based approaches. These technologies are becoming popular for their cost benefits and potential for mass production in the event of a pandemic.

“Several new antiviral agents, including short-interfering ribonucleic acids (siRNAs), antimicrobial peptides, and other anti-inflammatory drugs, are being evaluated in clinical trials for viral infections,” said Frost & Sullivan Healthcare Senior Research Analyst Aiswariya Chidambaram. “These ongoing clinical programs targeting newer classes of antivirals, vaccine technologies and improved diagnosis are likely to result in more sophisticated levels of treatment.”

While resistance to current drugs and viral/bacterial breakthrough remain key obstacles to effective treatment, the asymptomatic nature of sexually transmitted bacterial infections makes even diagnosis difficult. In many cases, genital infections caused by Chlamydia trachomatis and Neisseria gonorrhoea go unnoticed, as they are asymptomatic in up to 70 percent of infected women and up to 50 percent of infected men.

“Since preventative therapies can help control infectious diseases effectively, vaccines are the way forward, particularly for viral infections,” noted Chidambaram. “In fact, the global infectious diseases therapeutics market will be geared in this direction, as a way to significantly control disease burden.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Can Regenerative Medicine be the Cure for Cancer and Other Deadly Diseases?
Change in regulatory frameworks and standards are essential to expedite approval and release of innovative products.
Thursday, June 19, 2014
Strong Pipeline of mAbs Biosimilars in the US and Europe Lends Impetus to Global Market
The market is expected to soar from $1.2 billion of 2013 to $24 billion in 2019.
Tuesday, February 04, 2014
Bright Future Ahead for Biopharmaceutical Contract Manufacturing, Says Frost & Sullivan
New market insight uncovers the latest technology trends and strategic approaches for biopharma CMOs.
Tuesday, October 01, 2013
Molecular Farming Fits Need for Fully Functional Protein Therapeutics and Low-Cost Vaccines
Technology gains momentum through collaborations and licensing deals.
Monday, June 24, 2013
Frost & Sullivan Predicts Growth for the European Vaccines Market
Technology innovation and increasing focus on new vaccine development are likely to revolutionize the vaccine industry from prophylactic to therapeutic vaccines.
Friday, February 01, 2013
Scientific News
Madison Researchers Begin Work on Zika Virus
Work will start with basic questions about Zika virus infection.
Envigo Rat Models Proven to be Susceptible to Intra-Vaginal HSV-2 Infection and Protectable
Scientific findings establish the effectiveness of new approach to investigate the protective effects of vaccine candidates and anti-viral microbodies and to study asymptomatic primary genital HSV-2 infection.
Drug that Activates Innate Immune System Identified
Researchers from the institute have identified a drug, which is straightforward to synthesize and to couple to antigens that induce an immune response and may prove useful in the generation of vaccines.
Valvena, GSK Sign New R&D Collaboration
Valneva to supply process development services for EB66® -based Influenza vaccines.
Counting Cancer-busting Oxygen Molecules
Researchers from the Centre for Nanoscale BioPhotonics (CNBP), an Australian Research Centre of Excellence, have shown that nanoparticles used in combination with X-rays, are a viable method for killing cancer cells deep within the living body.
Therapeutic Approach Gives Hope for Multiple Myeloma
A new therapeutic approach tested by a team from Maisonneuve-Rosemont Hospital (CIUSSS-EST, Montreal) and the University of Montreal gives promising results for the treatment of multiple myeloma, a cancer of the bone marrow currently considered incurable with conventional chemotherapy and for which the average life expectancy is about 6 or 7 years.
Protein Protects Against Flu in Mice
The engineered molecule doesn’t provoke inflammation and may hail a new class of antivirals.
Crowdfunding the Fight Against Cancer
From budding social causes to groundbreaking businesses to the next big band, crowdfunding has helped connect countless worthy projects with like-minded people willing to support their efforts, even in small ways. But could crowdfunding help fight cancer?
Natural Protein Points to New Inflammation Treatment
Findings may offer insight to effective treatments for inflammatory diseases, such as rheumatoid arthritis, psoriasis, and multiple sclerosis.
Tricked-Out Immune Cells Could Attack Cancer
New cell-engineering technique may lead to precision immunotherapies.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!